Durvalumab for advanced, EGFR/ALK wild-type, high PD-L1 expression, non-small cell lung cancer- first line
Durvalumab is in development for patients with advanced/metastatic non-small cell lung cancer (NSCLC) who are EGFR/ALK wild-type and whose tumours have a high PD-L1 expression. NSCLC makes up the majority of lung cancers in the UK. Advanced/metastatic (Stage IV) NSCLC is when the cancer has spread beyond the lung which was initially affected, most often to the liver, the adrenal glands, the bones and the brain. Most patients with NSCLC are diagnosed at the advanced/metastatic stage where curative treatment with surgery is unsuitable. Currently, chemotherapy remains the first line treatment option but this is often not well tolerated by many patients.
Nivolumab in combination with chemotherapy for early-stage non-small cell lung cancer – neoadjuvant
Nivolumab in combination with chemotherapy is in clinical development as a neoadjuvant treatment for early-stage (stage IB-IIIA) operable non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Early-stage lung cancer is typically treated with surgery consisting of removing either part of or the whole of the lung, followed by chemotherapy and/or radiotherapy (adjuvant). However, the long-term outlook for patients undergoing this treatment pathway is still poor. Treatment with medicines prior to surgery (neoadjuvant) may provide better long-term survival prospects for patients with early-stage operable NSCLC.
Bulevirtide for chronic hepatitis delta virus infection
Bulevirtide is in clinical development for the treatment of chronic hepatitis Delta virus infection in adult patients with compensated liver disease. Hepatitis D is a viral infection of the liver that is dependent on the patient already being infected with hepatitis B virus. The co-infection is thought to be more severe and cause more damage to the liver than hepatitis B alone. Currently there are limited treatment options for the treatment of patients with chronic hepatitis D virus infection.
DermaSys for erectile dysfunction
DermaSys is in clinical development for treating erectile dysfunction (ED), which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. ED is very common, particularly in men over the age of 40 years. It can be caused by any number of physical and psychological factors. Any abnormality involving the nervous, circulatory or hormonal systems, whether due to medication or disease, may affect the ability to develop and sustain an erection. Although ED is a benign disorder, it may affect physical and psychosocial health and may have a significant impact on the quality of life of sufferers and their partners.
Nivolumab in combination with ipilimumab for early stage non-small cell lung cancer -neoadjuvant
Nivolumab in combination with ipilimumab is in clinical development as a neoadjuvant treatment for early stage (stage IB-IIIA), resectable non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Early stage lung cancer is typically treated with surgery consisting of removing either part of the affected lung or the whole lung, followed by chemotherapy and/or radiotherapy. However, the long-term outlook for patients undergoing this treatment pathway is still poor. Neoadjuvant therapy, which is administered prior to surgery to reduce the tumour size, may provide better long-term survival prospects for patients with early-stage operable NSCLC.
Daratumumab in addition to cyclophosphamide, bortezomib and dexamethasone for newly diagnosed systemic amyloid light-chain amyloidosis
Daratumumab in addition to cyclophosphamide, bortezomib and dexamethasone (CyBorD) is in clinical development for newly diagnosed systemic amyloid light-chain (AL) amyloidosis in adults. AL amyloidosis belongs to a group of diseases called systemic amyloidosis in which deposits of proteins (called amyloids) accumulate and cause damage in tissues and organs such as the kidneys, liver, gut, heart and nerves. In AL amyloidosis, the deposits are made up of proteins (called immunoglobulin light chains) produced in excess by malfunctioning white blood cells in the bone marrow.
Tepotinib for advanced non-small cell lung cancer harbouring MET exon14- skipping mutations
Tepotinib is in clinical development for patients with advanced non-small cell lung cancer (NSCLC) whose tumours have alterations in the MET gene. Advanced/metastatic (stage IV) NSCLC is when the cancer has spread to other organs most often to the liver, the adrenal glands, the bones and the brain. NSCLC is called locally advanced when it has spread into tissues around the lungs. Symptoms of NSCLC include fatigue, cough, shortness of breath, loss of appetite, coughing up phlegm, mucus or blood and chest pain. Most patients with metastatic NSCLC are diagnosed at the late stage where curative treatment with surgery is unsuitable. Currently, chemotherapy remains the main first line treatment option at this stage and is often not well tolerated by many patients.
Mepolizumab for hypereosinophilic syndrome – add-on therapy
Mepolizumab is a medicinal product currently in development as an add-on for the treatment of hypereosinophilic syndrome (HES). HES is a rare group of inflammatory disorders characterised by an overproduction of eosinophils (a type of disease-fighting white blood cell). When eosinophils infiltrate certain tissues, they can cause inflammation and organ damage which, over time, can impact patients’ day-to-day ability to function. Although any organ system can be involved in HES, the heart, central nervous system, skin, and respiratory tract are the most commonly affected.
Lasmiditan for acute treatment of migraine
Lasmiditan is a medicinal product currently in clinical development for the acute treatment of migraine. A migraine is usually a moderate or severe headache felt as a throbbing pain on one side of the head. Many people also have symptoms such as nausea, vomiting and increased sensitivity to light or sound. Migraines may be with aura (specific warning signs just before the migraine begins, such as seeing flashing lights), although the most common type is without aura (no specific warning signs).